Spots Global Cancer Trial Database for refractory malignant neoplasm

Every month we try and update this database with for refractory malignant neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers	NCT01624766	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali...	Anakinra Denosumab Everolimus	18 Years -	M.D. Anderson Cancer Center
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer	NCT01582191	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali...	Everolimus Laboratory Biom... Pharmacological... Vandetanib	-	M.D. Anderson Cancer Center
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations	NCT01531361	Advanced Malign... BRAF Gene Mutat... Metastatic Mali... Recurrent Malig... Refractory Mali...	Crizotinib Laboratory Biom... Pharmacological... Sorafenib Tosyl... Vemurafenib	18 Years -	M.D. Anderson Cancer Center
Financial Distress in Advanced Cancer Patients	NCT04053517	Advanced Malign... Locally Advance... Metastatic Mali... Recurrent Malig... Refractory Mali...	Medical Chart R... Quality-of-Life... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes	NCT02286687	Advanced Malign... ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... Metastatic Mali... PALB2 Gene Muta... Recurrent Malig... Refractory Mali...	Laboratory Biom... Pharmacological... Talazoparib	18 Years -	M.D. Anderson Cancer Center
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer	NCT03203525	Advanced Malign... Colorectal Carc... Metastatic Mali... Refractory Mali...	Bevacizumab Fluorouracil Leucovorin Oxaliplatin Pegylated Lipos... Temsirolimus Tumor Treating ...	18 Years -	M.D. Anderson Cancer Center
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	NCT02143401	Cirrhosis Hepatitis B Inf... Hepatitis C Inf... Metastatic Mali... Recurrent Hepat... Recurrent Malig... Refractory Mali... Stage IV Hepato... Unresectable So...	Laboratory Biom... Navitoclax Pharmacological... Sorafenib Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	NCT02143401	Cirrhosis Hepatitis B Inf... Hepatitis C Inf... Metastatic Mali... Recurrent Hepat... Recurrent Malig... Refractory Mali... Stage IV Hepato... Unresectable So...	Laboratory Biom... Navitoclax Pharmacological... Sorafenib Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors	NCT03108131	Skin Squamous C... Appendix Adenoc... Rare Lesion Locally Advance... Locally Advance... Metastatic Mali... Metastatic Skin... Metastatic Smal... Rare Neoplastic... Refractory Mali... Stage IV Small ... Unresectable Ma...	Atezolizumab Cobimetinib	18 Years -	M.D. Anderson Cancer Center
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer	NCT02595866	AIDS-Related No... Clinical Stage ... Clinical Stage ... Hepatocellular ... HIV Infection Kaposi Sarcoma Locally Advance... Locally Advance... Metastatic Lung... Metastatic Mali... Metastatic Mela... Non-Hodgkin Lym... Recurrent Class... Recurrent Malig... Refractory Clas... Refractory Mali... Stage III Lung ... Stage IV Lung C... Unresectable Me...	Antiretroviral ... Biopsy Biospecimen Col... Computed Tomogr... Pembrolizumab Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes	NCT02286687	Advanced Malign... ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... Metastatic Mali... PALB2 Gene Muta... Recurrent Malig... Refractory Mali...	Laboratory Biom... Pharmacological... Talazoparib	18 Years -	M.D. Anderson Cancer Center
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer	NCT03203525	Advanced Malign... Colorectal Carc... Metastatic Mali... Refractory Mali...	Bevacizumab Fluorouracil Leucovorin Oxaliplatin Pegylated Lipos... Temsirolimus Tumor Treating ...	18 Years -	M.D. Anderson Cancer Center
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer	NCT01582191	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali...	Everolimus Laboratory Biom... Pharmacological... Vandetanib	-	M.D. Anderson Cancer Center
Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer	NCT02491632	Advanced Malign... Fatigue Metastatic Mali... Recurrent Malig... Refractory Mali...	Dexamethasone Exercise Interv... Laboratory Biom... Quality-of-Life... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
PCRC-Supported Legacy Intervention in Pediatric Palliative Care	NCT04059393	Care Giver Recurrent Malig... Refractory Mali...	Internet-Based ... Best Practice Quality-of-Life... Questionnaire A...	7 Years - 17 Years	Vanderbilt-Ingram Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: